{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:13:42Z","timestamp":1786986822505,"version":"build-2736575974"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T00:00:00Z","timestamp":1738627200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-breast-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clbc.2024.12.002","type":"journal-article","created":{"date-parts":[[2024,12,13]],"date-time":"2024-12-13T12:26:11Z","timestamp":1734092771000},"page":"261-267.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+\/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study"],"prefix":"10.1016","volume":"25","author":[{"given":"Shari B.","family":"Goldfarb","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah L.","family":"Sammons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L.","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Pluard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon N.","family":"Jenkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry S.","family":"Komm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Portman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2024.12.002_bib0001","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11226723","article-title":"Sexual health after a breast cancer diagnosis: addressing a forgotten aspect of survivorship","volume":"11","author":"Vegunta","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.clbc.2024.12.002_bib0002","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3390\/jpm5020050","article-title":"Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue","volume":"5","author":"Lester","year":"2015","journal-title":"J Pers Med"},{"key":"10.1016\/j.clbc.2024.12.002_bib0003","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1200\/JOP.18.00710","article-title":"Managing genitourinary syndrome of menopause in breast cancer survivors receiving endocrine therapy","volume":"15","author":"Sussman","year":"2019","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.clbc.2024.12.002_bib0004","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1097\/GME.0000000000000329","article-title":"Vulvovaginal atrophy terminology consensus conference P. genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society","volume":"21","author":"Portman","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0005","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1097\/00001813-200409000-00003","article-title":"Acute effects of tamoxifen and third-generation aromatase inhibitors on menopausal symptoms of breast cancer patients","volume":"15","author":"Morales","year":"2004","journal-title":"Anticancer Drugs"},{"key":"10.1016\/j.clbc.2024.12.002_bib0006","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10549-006-9260-6","article-title":"Quality of life of postmenopausal women in the ATAC (\"Arimidex\", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer","volume":"100","author":"Cella","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2024.12.002_bib0007","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1080\/13697130802244422","article-title":"A survey among breast cancer survivors: treatment of the climacteric after breast cancer","volume":"11","author":"Antoine","year":"2008","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2024.12.002_bib0008","doi-asserted-by":"crossref","first-page":"26 e21-27","DOI":"10.1016\/j.ajog.2010.08.035","article-title":"Urogenital disorders in women with adjuvant endocrine therapy after early breast cancer","volume":"204","author":"Baumgart","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0009","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/13697137.2011.620658","article-title":"Menopausal-type symptoms among breast cancer patients on aromatase inhibitor therapy","volume":"15","author":"Gallicchio","year":"2012","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2024.12.002_bib0010","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3109\/13697137.2013.819327","article-title":"Prevalence of menopausal symptoms and their influence on adherence in women with breast cancer","volume":"17","author":"Kyvernitakis","year":"2014","journal-title":"Climacteric"},{"key":"10.1016\/j.clbc.2024.12.002_bib0011","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.3390\/curroncol29030149","article-title":"Gynecologic symptoms among hormone receptor-positive breast cancer patients on oral endocrine therapy: a cross-sectional study","volume":"29","author":"Moskalewicz","year":"2022","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0012","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/GME.0b013e31826560da","article-title":"Sexual dysfunction in women on adjuvant endocrine therapy after breast cancer","volume":"20","author":"Baumgart","year":"2013","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0013","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/GME.0b013e31829e41df","article-title":"Aromatase inhibitors affect vaginal proliferation and steroid hormone receptors","volume":"21","author":"Kallak","year":"2014","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0014","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00520-023-07742-2","article-title":"Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors","volume":"31","author":"Uslu","year":"2023","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.clbc.2024.12.002_bib0015","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1097\/GME.0000000000001609","article-title":"The 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society","volume":"27","year":"2020","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0016","doi-asserted-by":"crossref","first-page":"71","DOI":"10.5306\/wjco.v13.i2.71","article-title":"Management of genitourinary syndrome of menopause in breast cancer survivors: An update","volume":"13","author":"Lubi\u00e1n L\u00f3pez","year":"2022","journal-title":"World J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0017","series-title":"Tablets, for Oral Use Prescribing Information","year":"2023"},{"key":"10.1016\/j.clbc.2024.12.002_bib0018","series-title":"Vaginal Insert Prescribing Information","year":"2020"},{"key":"10.1016\/j.clbc.2024.12.002_bib0019","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA: A Cancer J Clin"},{"key":"10.1016\/j.clbc.2024.12.002_bib0020","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1093\/jnci\/djac158","article-title":"Estimation of the number of individuals living with metastatic cancer in the United States","volume":"114","author":"Gallicchio","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2024.12.002_bib0021","unstructured":"American Cancer Society. About breast cancer. Available at: https:\/\/www.cancer.org\/cancer\/types\/breast-cancer\/about.html. Accessed May 24, 2024."},{"key":"10.1016\/j.clbc.2024.12.002_bib0022","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1517\/17460441.2011.547188","article-title":"from the preclinical drug discovery to the treatment of postmenopausal osteoporosis","volume":"6","author":"Gennari","year":"2011","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.clbc.2024.12.002_bib0023","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.annonc.2023.09.3104","article-title":"Lasofoxifene versus fulvestrant for ER+\/HER2- metastatic breast cancer with an ESR1 mutation: Results from the randomized, phase 2 ELAINE 1 trial","volume":"34","author":"Goetz","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0024","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/GME.0000000000002355","article-title":"Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials","volume":"31","author":"Kagan","year":"2024","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0025","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jsxm.2016.11.317","article-title":"Validation of clinical tools for vaginal and vulvar symptom assessment in cancer patients and survivors","volume":"14","author":"Eaton","year":"2017","journal-title":"J Sex Med"},{"key":"10.1016\/j.clbc.2024.12.002_bib0026","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1016\/j.jsxm.2016.02.011","article-title":"Lasofoxifene, a selective estrogen receptor modulator, as a treatment for sexual dysfunction in postmenopausal women","volume":"13","author":"Kingsberg","year":"2016","journal-title":"J Sex Med"},{"key":"10.1016\/j.clbc.2024.12.002_bib0027","first-page":"1379","article-title":"Reported sexual activity and orgasm frequency in a comparative study of the SERMs lasofoxifene and raloxifene in an osteoporosis prevention study","volume":"23","author":"Krychman","year":"2016","journal-title":"Menopause"},{"key":"10.1016\/j.clbc.2024.12.002_bib0028","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.clbc.2017.05.008","article-title":"Vaginal atrophy in breast cancer survivors: attitude and approaches among oncologists","volume":"17","author":"Biglia","year":"2017","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.clbc.2024.12.002_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.955057","article-title":"Sexual dysfunction as a challenge in treated breast cancer: in-depth analysis and risk assessment to improve individual outcomes","volume":"12","author":"Hern\u00e1ndez-Blanquisett","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0030","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.3390\/curroncol30020112","article-title":"Adherence to adjuvant endocrine therapy in breast cancer patients","volume":"30","author":"Rosso","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0031","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1200\/JCO.2010.28.9199","article-title":"Breast carcinomas arising at a young age: unique biology or a surrogate for aggressive intrinsic subtypes?","volume":"29","author":"Anders","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0032","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.1200\/JCO.2007.14.2471","article-title":"Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression","volume":"26","author":"Anders","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0033","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","article-title":"Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the Suppression of Ovarian Function Trial","volume":"34","author":"Ribi","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0034","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1200\/JCO.22.00577","article-title":"Postoperative adjuvant anastrozole for 10 or 5 years in patients with hormone receptor-positive breast cancer: AERAS, a randomized multicenter open-label phase III trial","volume":"41","author":"Iwase","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clbc.2024.12.002_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10549-020-05622-5","article-title":"Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy","volume":"181","author":"Ribi","year":"2020","journal-title":"Breast Cancer Res Treat"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820924003392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,14]],"date-time":"2025-03-14T05:57:00Z","timestamp":1741931820000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820924003392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S1526820924003392"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.002","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+\/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2024.12.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}